These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8841971)

  • 41. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.
    Green AJ; Harvey RJ; Thompson EJ; Rossor MN
    Neurosci Lett; 1999 Jan; 259(2):133-5. PubMed ID: 10025576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.
    Geijselaers SLC; Aalten P; Ramakers IHGB; De Deyn PP; Heijboer AC; Koek HL; OldeRikkert MGM; Papma JM; Reesink FE; Smits LL; Stehouwer CDA; Teunissen CE; Verhey FRJ; van der Flier WM; Biessels GJ;
    J Alzheimers Dis; 2018; 61(1):309-320. PubMed ID: 29154275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
    Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
    Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.
    Shoji M; Matsubara E; Murakami T; Manabe Y; Abe K; Kanai M; Ikeda M; Tomidokoro Y; Shizuka M; Watanabe M; Amari M; Ishiguro K; Kawarabayashi T; Harigaya Y; Okamoto K; Nishimura T; Nakamura Y; Takeda M; Urakami K; Adachi Y; Nakashima K; Arai H; Sasaki H; Kanemaru K; Yamanouchi H; Yoshida Y; Ichise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Yoshida H; Toji H; Nakamura S; Hirai S
    Neurobiol Aging; 2002; 23(3):363-70. PubMed ID: 11959397
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Tau protein. A potential biological indicator for early detection of Alzheimer disease].
    Buch K; Riemenschneider M; Bartenstein P; Willoch F; Müller U; Schmolke M; Nolde T; Steinmann C; Guder WG; Kurz A
    Nervenarzt; 1998 May; 69(5):379-85. PubMed ID: 9629553
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.
    Itoh N; Arai H; Urakami K; Ishiguro K; Ohno H; Hampel H; Buerger K; Wiltfang J; Otto M; Kretzschmar H; Moeller HJ; Imagawa M; Kohno H; Nakashima K; Kuzuhara S; Sasaki H; Imahori K
    Ann Neurol; 2001 Aug; 50(2):150-6. PubMed ID: 11506396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Relation to dementia, apolipoprotein E polymorphism, cerebral atrophy, and white matter lesions.
    Skoog I; Hesse C; Fredman P; Andreasson LA; Palmertz B; Blennow K
    Arch Neurol; 1997 Mar; 54(3):267-72. PubMed ID: 9074395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus.
    Lins H; Wichart I; Bancher C; Wallesch CW; Jellinger KA; Rösler N
    J Neural Transm (Vienna); 2004 Mar; 111(3):273-80. PubMed ID: 14991454
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology.
    Arai H; Morikawa Y; Higuchi M; Matsui T; Clark CM; Miura M; Machida N; Lee VM; Trojanowski JQ; Sasaki H
    Biochem Biophys Res Commun; 1997 Jul; 236(2):262-4. PubMed ID: 9240421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
    Tapiola T; Pirttilä T; Mehta PD; Alafuzofff I; Lehtovirta M; Soininen H
    Neurobiol Aging; 2000; 21(5):735-40. PubMed ID: 11016543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
    Nitsch RM; Rebeck GW; Deng M; Richardson UI; Tennis M; Schenk DB; Vigo-Pelfrey C; Lieberburg I; Wurtman RJ; Hyman BT
    Ann Neurol; 1995 Apr; 37(4):512-8. PubMed ID: 7717688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
    Vijayaraghavan S; Maetzler W; Reimold M; Lithner CU; Liepelt-Scarfone I; Berg D; Darreh-Shori T
    Alzheimers Dement; 2014 Sep; 10(5):530-540.e1. PubMed ID: 23978325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased tau protein level in postmortem cerebrospinal fluid.
    Morihara T; Kudo T; Ikura Y; Kashiwagi Y; Miyamae Y; Nakamura Y; Tanaka T; Shinozaki K; Nishikawa T; Takeda M
    Psychiatry Clin Neurosci; 1998 Feb; 52(1):107-10. PubMed ID: 9682942
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
    Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.